Remove Presentation Remove Vaccine Remove Virus
article thumbnail

Scientists Developing Vaccine Against Present and Future COVID Viruses

Drugs.com

MONDAY, May 6, 2024 -- Scientists are busy working on a vaccine that might fight strains of the COVID virus SARS-CoV-2 that haven't even emerged yet.The effort from a British team at the University of Cambridge is already showing promise in mouse.

Virus 290
article thumbnail

Advancing vaccine design: potential of peptide mimicry

Drug Target Review

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. Since December 2019, SARS-CoV-2 (COVID-19) infection has become a worldwide urgent public health concern.

Vaccine 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

mRNA Therapeutics: Revolutionizing Treatment Beyond Vaccines

DrugBank

The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. However, mRNA technology has introduced new possibilities, particularly in developing personalized cancer vaccines and combination therapies. Another challenge is the potential for unintended immune responses.

Vaccine 97
article thumbnail

AZD1222 Vaccine Met Primary Efficacy Endpoint in Preventing COVID-19

The Pharma Data

. Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine.

Vaccine 52
article thumbnail

Researchers find potential path to a broadly protective COVID-19 vaccine using T cells

The Pharma Data

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. These epitopes could then be used in a vaccine to train T cells, providing protective immunity.

Vaccine 52
article thumbnail

CureVac provides update on Phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV

The Pharma Data

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. 37, first identified in Peru (21%) and B.1.621,

Vaccine 52
article thumbnail

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study

The Pharma Data

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.